Matt Barnes, Heptares Therapeutics president and head of UK R&D
Sosei Heptares partners with a UK-based cancer research organization to bring its drug to trial
Cancer research has been a focus for Sosei Heptares for several years, and their latest deal hopes to progress one of their newer therapies. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
